Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2006, Article ID 39130, 3 pages
http://dx.doi.org/10.1155/SRCM/2006/39130
Case Report

Primary Cardiac Angiosarcoma

1Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA
2Division of Hematology/Oncology, Worcester Medical Center, Fallon Clinic, Worcester, MA 01608, USA

Received 31 May 2005; Revised 4 June 2006; Accepted 8 June 2006

Copyright © 2006 Dhatri Kodali and Kala Seetharaman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P Baay, S V Karwande, J P Kushner, S Olsen, and D G Renlund, “Successful treatment of a cardiac angiosarcoma with combined modality therapy,” Journal of Heart and Lung Transplantation, vol. 13, no. 5, pp. 923–925, 1994. View at Google Scholar
  2. D Bafaloukos, C Papadimitriou, H Linardou et al., “Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group,” British Journal of Cancer, vol. 91, no. 9, pp. 1639–1644, 2004. View at Publisher · View at Google Scholar
  3. T Chidiac, G T Budd, R Pelley et al., “Phase II trial of liposomal doxorubicin (Doxil®) in advanced soft tissue sarcomas,” Investigational New Drugs, vol. 18, no. 3, pp. 253–259, 2000. View at Publisher · View at Google Scholar
  4. M G Crespo, L A Pulpon, G Pradas et al., “Heart transplantation for cardiac angiosarcoma: should its indication be questioned?” Journal of Heart and Lung Transplantation, vol. 12, no. 3, pp. 527–530, 1993. View at Google Scholar
  5. F Fata, E O'Reilly, D Ilson et al., “Paclitaxel in the treatment of patients with anglosarcoma of the scalp or face,” Cancer, vol. 86, no. 10, pp. 2034–2037, 1999. View at Publisher · View at Google Scholar
  6. A A Garcia, R A Kempf, M Rogers, and F M Muggia, “A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas,” Annals of Oncology, vol. 9, no. 10, pp. 1131–1133, 1998. View at Publisher · View at Google Scholar
  7. M A Herrmann, R A Shankerman, W D Edwards, C Shub, and H V Schaff, “Primary cardiac angiosarcoma: a clinicopathologic study of six cases,” Journal of Thoracic and Cardiovascular Surgery, vol. 103, no. 4, pp. 655–664, 1992. View at Google Scholar
  8. D T Janigan, A Husain, and N A Robinson, “Cardiac angiosarcomas. A review and a case report,” Cancer, vol. 57, no. 4, pp. 852–859, 1986. View at Publisher · View at Google Scholar
  9. I Judson, J A Radford, M Harris et al., “Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 37, no. 7, pp. 870–877, 2001. View at Publisher · View at Google Scholar
  10. S Kakizaki, H Takagi, and Y Hosaka, “Cardiac angiosarcoma responding to multidisciplinary treatment,” International Journal of Cardiology, vol. 62, no. 3, pp. 273–275, 1997. View at Publisher · View at Google Scholar
  11. A Llombart-Cussac, X Pivot, G Contesso et al., “Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience,” British Journal of Cancer, vol. 78, no. 12, pp. 1624–1628, 1998. View at Google Scholar
  12. R E Michler and D J Goldstein, “Treatment of cardiac tumors by orthotopic cardiac transplantation,” Seminars in Oncology, vol. 24, no. 5, pp. 534–539, 1997. View at Google Scholar
  13. B Movsas, J Teruya-Feldstein, J Smith, E Glatstein, and A H Epstein, “Primary cardiac sarcoma: a novel treatment approach,” Chest, vol. 114, no. 2, pp. 648–652, 1998, Selected Reports. View at Google Scholar
  14. J B Jr Putnam, M S Sweeney, R Colon, L A Lanza, O H Frazier, and D A Cooley, “Primary cardiac sarcomas,” Annals of Thoracic Surgery, vol. 51, no. 6, pp. 906–910, 1991. View at Google Scholar
  15. K M Skubitz, “Phase II trial of pegylated-liposomal doxorubicin (DoxilTM) in sarcoma,” Cancer Investigation, vol. 21, no. 2, pp. 167–176, 2003. View at Publisher · View at Google Scholar
  16. K M Skubitz and P A Haddad, “Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma,” Cancer, vol. 104, no. 2, pp. 361–366, 2005. View at Publisher · View at Google Scholar
  17. S Stewart, H Jablonowski, F D Goebel et al., “Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 683–691, 1998. View at Google Scholar
  18. S M Talbot, R N Taub, M L Keohan, N Edwards, M E Galantowicz, and L L Schulman, “Combined heart and lung transplantation for unresectable primary cardiac sarcoma,” Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 6, pp. 1145–1148, 2002. View at Publisher · View at Google Scholar
  19. S Toma, A Tucci, G Villani, G Carteni, N Spadini, and R Palumbo, “Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG),” Anticancer Research, vol. 20, no. 1 B, pp. 485–491, 2000. View at Google Scholar